Low-risk papillary thyroid microcarcinoma
Conditions
Interventions
Group A (TSH suppression treatment group):According to the patients condition and TSH level, 90 patients were given appropriate dose of thyroid hormone replacement therapy to maintain TSH at a low lev
Group B (control group) :90 cases only received routine follow-up observation without TSH suppression therapy.
Sponsors
Beijing Tongren Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Family history of thyroid cancer and radiation exposure during adolescence. 2. Pathologically confirmed papillary thyroid carcinoma with a diameter less than 10mm; 3. No distant metastasis, no external thyroid invasion, no lymph node metastasis, no pathological high-risk subtypes, no tracheal or recurrent laryngeal nerve invasion and other clinical high-risk factors; 4. Aged between 18 and 75, male or non-pregnant or non-lactating female; 5. Normal function of major organs and stable vital signs; 6. Complete clinical data of patients; 7. Able to comply with the study visit schedule, and understand and comply with all test protocol requirements; 8. Able and willing to sign informed consent.
Exclusion criteria
Exclusion criteria: Subjects will not be admitted to the study if they meet any of the following criteria: 1. The psychological test questionnaire indicated that patients with anxiety type, sensitive type or high anxiety value; 2. Tumor growth exceeding 3mm or tumor diameter greater than 10mm was found during follow-up; 3. Patients with severe cardiac, liver and renal insufficiency; 4. Patients with grade I or above coronary heart disease, arrhythmias (including prolonged QTc interval > 450 ms in men and > 470 ms in women) and cardiac insufficiency; 5. Osteoporosis, hypocalcemia; 6. Patients with other malignant tumors; 7. Allergic patients have been confirmed to the drugs used in this study; 8. Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders; 9. Participate in other drug clinical trials as a subject, and the last trial drug administration is less than 4 weeks after the first administration of the drug in this study; 10. Patients with other concomitant diseases that, in the judgment of the investigator, endanger the patient's safety or affect the patient's completion of the study; 11. Plan to receive any other antitumor therapy during this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid Stimulating Hormone;Tumor size; | — |
Secondary
| Measure | Time frame |
|---|---|
| Location of the tumor;Tumor echogenicity;Relationship between tumor and capsule and relationship with nerve; | — |
Countries
China
Contacts
Public ContactChen Xiaohong
Beijing Tongren Hospital Affiliated to Capital Medical University
Outcome results
None listed